Inogen, Inc. (INGN)

Intra-Cellular Therapies Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	339.96	335.71	315.66	377.24	358	308.49
Revenue Growth (YoY)	5.73%	6.35%	-16.32%	5.37%	16.05%	-14.77%
Cost of Revenue	183.22	180.96	188.96	223.71	181.52	170.31
Gross Profit	156.74	154.74	126.7	153.53	176.48	138.18
Selling, General & Admin	168.6	171.86	169.69	180.06	162.26	135.97
Research & Development	19.07	21.61	20.84	21.94	16.58	14.08
Operating Expenses	187.66	193.47	190.53	202	178.84	150.05
Operating Income	-30.92	-38.73	-63.83	-48.47	-2.36	-11.87
Interest & Investment Income	4.82	5.19	6.57	2.84	0.13	0.91
Currency Exchange Gain (Loss)	-0.2	-0.2	0.2	-0.8	-0.7	0.6
Other Non Operating Income (Expenses)	1.26	1.05	0.27	-0.06	-0.01	-0.06
EBT Excluding Unusual Items	-25.04	-32.69	-56.79	-46.49	-2.94	-10.43
Merger & Restructuring Charges	-0.55	-0.78	-5.84	-	-	-
Impairment of Goodwill	-	-	-32.89	-	-	-
Gain (Loss) on Sale of Assets	-	-	-	-52.16	-	-
Other Unusual Items	-2.43	-3	-6.82	15.39	11.6	5.15
Pretax Income	-28.02	-36.48	-102.34	-83.27	8.66	-5.28
Income Tax Expense	-0.54	-0.59	0.11	0.5	14.99	0.55
Net Income	-27.48	-35.89	-102.45	-83.77	-6.33	-5.83
Net Income to Common	-27.48	-35.89	-102.45	-83.77	-6.33	-5.83
Shares Outstanding (Basic)	24	24	23	23	22	22
Shares Outstanding (Diluted)	24	24	23	23	22	22
Shares Change (YoY)	3.53%	2.06%	1.42%	1.61%	2.32%	-1.17%
EPS (Basic)	-1.14	-1.52	-4.42	-3.67	-0.28	-0.27
EPS (Diluted)	-1.15	-1.52	-4.42	-3.67	-0.28	-0.27
Free Cash Flow	-19.04	-9.09	-29.75	-58.75	-0.3	19.67
Free Cash Flow Per Share	-0.79	-0.38	-1.28	-2.57	-0.01	0.90
Gross Margin	46.11%	46.09%	40.14%	40.70%	49.30%	44.79%
Operating Margin	-9.10%	-11.54%	-20.22%	-12.85%	-0.66%	-3.85%
Profit Margin	-8.08%	-10.69%	-32.45%	-22.21%	-1.77%	-1.89%
Free Cash Flow Margin	-5.60%	-2.71%	-9.43%	-15.57%	-0.08%	6.38%
EBITDA	-9.99	-17.73	-45.68	-24.95	19.27	6.71
EBITDA Margin	-2.94%	-5.28%	-14.47%	-6.62%	5.38%	2.17%
D&A For EBITDA	20.93	21	18.15	23.51	21.63	18.58
EBIT	-30.92	-38.73	-63.83	-48.47	-2.36	-11.87
EBIT Margin	-9.10%	-11.54%	-20.22%	-12.85%	-0.66%	-3.85%
Effective Tax Rate	-	-	-	-	173.14%	-
Revenue as Reported	339.96	335.71	315.66	377.24	358	308.49
Advertising Expenses	-	32.18	27.12	33.27	35.18	34.18

Updated Feb 28, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q